Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Besremi (ropeginterferon alfa-2B) to Treat Polycythaemia Vera

Drug Name

Besremi® (ropeginterferon alfa-2B)

Developer

PharmaEssentia, AOP Orphan Pharmaceuticals

Therapy Class

Interferon

Product Description

Mono-pegylated proline interferon

Current Indication

Polycythaemia vera

Market Sector

Oncology

Development Status

Approved in Europe
Expand
Close
Close
Close

Go Top